Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (100)	7/27/2000 10:06:19 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

they take known small molecule ligands and hook them together Seems like they'll run out of interesting targets in a hurry, while a company with HTS will be accumulating "somers". <g> From that perspective..... why not pick up DGI (and the patent) and revise the S-1? Since DGI is currently valued at MINUS $40 million (my ballpark estimate only, please get your own!!), I'm certain that NBSC will accept an offer of $0. No? Whether they're drugs or not . . . . While we've got your brain to pick...... how many companies are exploring pulmonary delivery for stuff that, at first blush, may not look drug-like?